Diligence memo · auto-generated · as of July 2, 2026
Recode Therapeutics, Inc.
Recode Therapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Recode Therapeutics, Inc. operates in Biotechnology, based in Menlo Park.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Recode Therapeutics, Inc. has raised $319M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $260M on 2021-10-13.
Most recent recorded round closed around 2025-09-23.
Valuation (modeled)modeled
Provath models Recode Therapeutics, Inc. at approximately $215M (range $133M–$260M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.24× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 98% of Biotechnology peers (4293 compared).
Modeled value ranks above 73% of those peers.
Closest niche peers: Kriya Therapeutics, Inc., Pathos AI, Inc., Sensei Biotherapeutics, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.